STOCK TITAN

Supernus Pharmaceuticals Inc - SUPN STOCK NEWS

Welcome to our dedicated news page for Supernus Pharmaceuticals (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Supernus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Supernus Pharmaceuticals's position in the market.

Rhea-AI Summary
Supernus Pharmaceuticals resubmits New Drug Application for apomorphine infusion device for Parkinson's disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
-
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. will host an R&D Day on October 18, 2023, to discuss its pipeline and clinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
Rhea-AI Summary
Supernus Pharmaceuticals presents new data on Qelbree's efficacy in pediatric and adult patients with ADHD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Supernus Pharmaceuticals CEO to participate in fireside chat at 2023 Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
conferences
-
Rhea-AI Summary
Bethany L. Sensenig joins Supernus Pharmaceuticals' Board of Directors, bringing industry knowledge and expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.23%
Tags
earnings
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will report Q2 2023 financial and business results on August 8. A conference call will be hosted by the President and CEO, Jack Khattar, and CFO, Tim Dec, at 4:30 p.m. ET. A live webcast and replay will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
earnings
-
Rhea-AI Summary
Supernus Pharmaceuticals' CEO will participate in a fireside chat at the Jefferies Healthcare Conference on June 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences
-
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. announces first quarter 2023 financial results, with total revenues of $153.8 million and net product sales increase of 25%. Raises full year 2023 GAAP and non-GAAP operating earnings guidance. Qelbree continues to expand its base of prescribers and total IQVIA prescriptions increase by 14%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
Supernus Pharmaceuticals Inc

Nasdaq:SUPN

SUPN Rankings

SUPN Stock Data

1.87B
47.71M
5.12%
107.86%
9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Rockville

About SUPN

pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.